Sera Prognostics, INC

Sera Prognostics announced its second quarter 2026 financial results, detailing progress in commercial adoption, regulatory milestones, and scientific validation of its PreTRM test.

Sera Prognostics, Inc. announced the appointment of Mark Capone, an experienced healthcare executive, to its Board of Directors, effective July 1, 2026.

Sera Prognostics, Inc. successfully held its 2026 Annual Meeting of Stockholders, confirming the election of two directors and the ratification of its independent auditor.

Sera Prognostics announced that director Jeffrey T. Elliott will step down from the Board of Directors effective June 4, 2026.

Sera Prognostics announced its first quarter 2026 financial results, highlighting progress in commercialization efforts and an extended cash runway through 2029.

Sera Prognostics announced its fourth quarter and full year 2025 financial results, highlighting the landmark PRIME Study publication and extended cash runway through 2028.

Sera Prognostics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued net losses, increased operating expenses, and strategic workforce reductions alongside positive clinical study results and expanded partnerships.

Sera Prognostics reports a strengthened cash position and strategic commercial expansion, supported by positive clinical trial results for its PreTRM test, despite ongoing net losses.

Sera Prognostics, a women's health company, reported a reduced net loss in Q2 2025, bolstered by a recent $53.6M capital raise and positive clinical trial data for its PreTRM test.

Sera Prognostics announces its Q1 2025 financial results, focusing on commercializing the PreTRM test and advancing its pipeline.

Sera Prognostics reports a net loss of $7.9 million for the third quarter of 2024, while strategically focusing on commercializing its PreTRM test and reducing operating expenses.

Sera Prognostics reported a net loss of $16.4 million for the first half of 2024, while focusing on commercializing its PreTRM test and advancing its product pipeline.

Sera Prognostics, a women's health company, reported a reduced net loss in 2025, bolstered by a recent capital raise and positive clinical trial results for its PreTRM test, while expanding its executive team and product pipeline.

Sera Prognostics' 2024 10-K filing details the company's financial performance and strategic advancements, particularly regarding its PreTRM test for preterm birth risk prediction.

Sera Prognostics has updated its non-employee director compensation policy and filed its annual report on Form 10-K for the fiscal year ended December 31, 2023.

Joshua Phillips, a Director of Sera Prognostics, Inc., reported multiple transactions in common stock on July 10, 2026.

Mansoor Raza Mirza, a Director of Sera Prognostics, Inc., reported multiple transactions in common stock on July 10, 2026.

Sandra Aj Lawrence, a Director of Sera Prognostics, Inc., reported multiple transactions in common stock on July 10, 2026.

Kim P. Kamdar, a Director of Sera Prognostics, Inc., reported multiple transactions in common stock on July 10, 2026.

Gregory C Critchfield, a Director of Sera Prognostics, Inc., reported multiple transactions in common stock on July 10, 2026.

Mark Christopher Capone, a Director of Sera Prognostics, Inc., reported multiple transactions in common stock on July 10, 2026.

Sera Prognostics announces its 2025 Annual Meeting of Stockholders to be held on June 5, 2025, outlining key voting items including the election of directors and ratification of Ernst & Young LLP as the independent auditor.

Sera Prognostics will hold its 2025 Annual Meeting of Stockholders virtually on June 5, 2025, to elect directors and ratify the appointment of its independent auditor.

Sera Prognostics has filed a definitive proxy statement with the Securities and Exchange Commission.

Sera Prognostics will hold its 2024 Annual Meeting of Stockholders virtually on June 6, 2024, to elect directors and ratify the appointment of its independent accounting firm.

Chione Ltd. and its associated reporting persons have increased their beneficial ownership in Sera Prognostics, Inc. to 7.6% of Class A Common Stock through a recent acquisition of 625,000 shares in a public offering.

Baker Bros. Advisors LP and its affiliates have substantially increased their beneficial ownership in Sera Prognostics, Inc. to 16.1% of Class A Common Stock, primarily through the acquisition of 11.25 million pre-funded warrants in a recent public offering.

Aberdeen Group plc and abrdn Inc. have reported a combined beneficial ownership of 7.21% in Sera Prognostics, Inc. Class A Common Stock.

Whetstone Capital Advisors and David Atterbury have filed a Schedule 13G reporting an 8.6% beneficial ownership stake in Sera Prognostics, Inc.

Whetstone Capital Advisors and David Atterbury have disclosed a 9.2% beneficial ownership stake in Sera Prognostics, Inc. Class A Common Stock.

Whetstone Capital Advisors and David Atterbury have disclosed a 9.9% beneficial ownership stake in Sera Prognostics, Inc. Class A Common Stock.

RA Capital Management and its affiliates have filed an amended Schedule 13G, reporting zero beneficial ownership in Sera Prognostics, Inc.'s Class A Common Stock as of June 30, 2025.

Aberdeen Group plc and abrdn Inc. have disclosed a 6.07% beneficial ownership stake in Sera Prognostics, Inc.'s Class A Common Stock.